国产替罗非班治疗急性冠状动脉综合征的安全性和有效性Effect of glycoprotein Ⅱb/Ⅲa receptor inhibitors in 146 patients with acute coronary syndromes
严金川,马根山,冯毅,沈成兴,戴启明,朱建
摘要(Abstract)：
目的观察国产血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班(欣维宁)在治疗急性冠状动脉综合征(ACS)中的安全性和有效性。方法146例ACS患者随机分为受试组(替罗非班+常规治疗组,73例)和对照组(常规治疗组,73例),疗程24h。结果替罗非班组24h及30d的主要不良心脏事件(MACE)发生率明显低于对照组(24h2.7%比15.1%;30d5.4%比24.7%,P<0.001)。替罗非班组肌钙蛋白T(cTnT)峰值水平(1.47±0.58μg/L)及24h平均水平(1.19±0.54μg/L)均明显较对照组(2.42±0.49μg/L和1.82±0.42μg/L)低(P均<0.01)。替罗非班组和对照组均未见大出血或小出血,皮肤、黏膜出血发生率分别为20.4%和18.9%,二组之间出血并发症发生率差异无统计学意义(P>0.05)。结论替罗非班在ACS的标准治疗基础上能进一步减少心肌缺血事件,并能减少心肌细胞的损伤,且安全性好。
关键词(KeyWords)： 冠状动脉疾病;血小板膜糖蛋白类;替罗非班
基金项目(Foundation):
作者(Author): 严金川,马根山,冯毅,沈成兴,戴启明,朱建
参考文献(References)：
- [1]Kim JH,Jeong MH,Rhew JY,et al.Long-term clinical outcomes of platelet glycoproteinⅡb/Ⅲa inhibitor combined with lowmolecular weight heparin in patients with acute coronary syndrome.Circ J,2005,69:159-164.
- [2]Vorchheiner DA,Badimon JJ,Fuster V.Platelet glycoproteinⅡb/Ⅲa receptor antagonists in cardiovascular disease.JAMA,1999,281:1407-1414.
- [3]Platelet Receptor Inhibition in Ischemic Syndrome Management(PRISM)Study Investigators.A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.N Eng J Med,1998,338:1498-1505.
- [4]James C.Bleeding complications of glycoproteinⅡb/Ⅲa receptor inhibitors.Am Heart J,1999,138:S287-294.
- [5]Jarvis B,Simpson K.Clopidogrel:a review of its use in the prevention of atherothrombosis.Drugs,2000,60:347-358.
- [6]Boersma E,Harrington RA,Moliterno DJ,et al.Platelet glycoproteinⅡb/Ⅲa inhibitors in acute coronary syndromes.Lancet,2002,359:189-198.
- [7]Lindahl B,Venge P,Wallentin L.Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease.Circulation,1996,93:1651-1657.